Pfizer Beats Q2 Estimates, Plans Additional $2.5 Billion in Cost Savings

Pfizer Inc. (PFE) on Tuesday reported second-quarter earnings that surpassed analyst expectations and announced plans for an additional $2.5 billion in cost reductions. The strong quarterly performance was largely driven by robust sales of its blockbuster blood thinner, Eliquis, helping to offset the continued decline in revenue from its COVID-19 products.

Strong Sales Drive Earnings Beat

Pfizer posted an adjusted profit of 77 cents per share for the second quarter, exceeding the 68 cents per share consensus estimate compiled by LSEG. The beat was fueled by standout performance from key drugs, most notably Eliquis, which the company markets with Bristol Myers Squibb.

• Eliquis Sales: Reached $2.43 billion, significantly above analysts’ estimates of $1.93 billion.
• Sales Growth: Eliquis sales rose 19% on an operational basis, which the company attributed to higher net pricing in the U.S., a favorable channel mix, and strong global demand.

Higher sales from the cancer therapy Padcev and a 25% operational increase in revenue from acquired products also contributed to the positive results, according to the company's report.

Cost Reductions and Updated Guidance

Ad

In a move to streamline operations and prepare for future growth, Pfizer unveiled a new cost-saving initiative. The company will target an additional $2.5 billion in savings, which it expects to realize between 2027 and 2029. This builds on an existing cost-reduction program aimed at navigating the post-pandemic market.

Reflecting its quarterly performance, Pfizer raised the lower end of its full-year sales forecast. The company now expects annual sales of $60.5 billion to $62.5 billion, up from its previous range of $59.5 billion to $62.5 billion. However, it reaffirmed its annual profit forecast, noting a $650 million impact from a recent licensing deal with China’s Innovent Biologics.

Strategic Focus on Future Growth

Pfizer's strategy centers on offsetting declining COVID-related revenue by focusing on newer medicines and strategic acquisitions. Investors are closely watching the company's progress in the high-growth obesity drug market, particularly following its $10 billion acquisition of Metsera.

CEO Albert Bourla stated that the company’s "launched and acquired products performed well" and noted that its "obesity program is advancing with meaningful momentum." Pfizer has previously indicated that it expects to return to stronger growth after 2028. Despite the positive report, shares of the drugmaker were flat in premarket trading.